IRCT20171118037528N1.
Trial name or title | Acronym: — |
Methods |
Type of trial: efficacy trial Allocation: randomised Intervention model: parallel assignment Masking: double‐blinded (participants and administrators) Primary purpose: treatment |
Participants |
Condition: type 2 diabetes mellitus Enrolment: estimated 72 Inclusion criteria
Exclusion criteria
|
Interventions |
Intervention(s): resveratrol (500 mg oral 2 times a day) Comparator(s): placebo capsules |
Outcomes |
Primary outcome(s): peroxisome proliferator‐activated receptor alpha, p53 gene, p21 gene, p16 gene, soluble cluster of differentiation 163, TNF‐related weak inducer of apoptosis Secondary outcome(s): total triglycerides, total cholesterol, high‐density lipoprotein cholesterol, low‐density lipoprotein cholesterol, fasting blood glucose, glycated haemoglobin, fasting insulin Other outcome(s): — |
Starting date |
Trial start date: July 2018 Trial completion date: not reported |
Contact information | Responsible party/principal investigator: Shima Abdollahi, Shahid Sadoughi University of Medical Science |
Study identifier | Trial identifier:IRCT20171118037528N1 |
Official title | Effects of resveratrol on lipid and glycemic profile indices, expression of PPARα, some factors associated with cell cycle arrest and sCD163 to sTWEAK ratio in T2DM patients |
Stated purpose of study | Quote: "effects of resveratrol on lipid and glycemic profile indices, expression of PPARα, some factors associated with cell cycle arrest and sCD163 to sTWEAK ratio in T2DM patients" |
Notes |